.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after an average consequence of 11 months, clients along with metastatic gastrointestinal cysts that received biomarker-matched therapies based upon spreading cyst DNA profiling revealed a higher clinical advantage than those acquiring unparalleled treatment.